Terms: = Colorectal cancer AND JAK3, L-JAK, 3718, ENSG00000105639, P52333, JAKL, JAK-3, LJAK, JAK3_HUMAN AND Treatment
4 results:
1. Novel Potent EGFR-jak3 Dual-Target Inhibitor that Overcomes KRAS Mutation Resistance in colorectal cancer.
Wu T; Yu J; Wang C; Jin Y; Zheng X; Chen L; Ma X; Sun X
Anticancer Agents Med Chem; 2023; 23(4):440-449. PubMed ID: 35692150
[TBL] [Abstract] [Full Text] [Related]
2. Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells.
Huang J; Zhou Y; Zhong X; Su F; Xu L
Oxid Med Cell Longev; 2022; 2022():3129155. PubMed ID: 35281458
[TBL] [Abstract] [Full Text] [Related]
3. Factors determining low anterior resection syndrome after rectal cancer resection: A study in Thai patients.
Ekkarat P; Boonpipattanapong T; Tantiphlachiva K; Sangkhathat S
Asian J Surg; 2016 Oct; 39(4):225-31. PubMed ID: 26340884
[TBL] [Abstract] [Full Text] [Related]
4. Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells.
Murata T; Noguchi PD; Puri RK
J Biol Chem; 1995 Dec; 270(51):30829-36. PubMed ID: 8530527
[TBL] [Abstract] [Full Text] [Related]
